Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT ID: NCT06924606
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
66 participants
INTERVENTIONAL
2025-07-15
2026-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
JS207 injection +docetaxel
Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
Arm B
Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
JS207 injection +JS004 injection
Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
Arm C
Patients receive JS207 10mg/kg or other dosage .
JS207 injection
Patients receive JS207 10mg/kg or other dosage.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JS207 injection +docetaxel
Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
JS207 injection +JS004 injection
Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
JS207 injection
Patients receive JS207 10mg/kg or other dosage.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel); or who have failed sequential first- and second-line treatment with PD-1/PD-L1 inhibitors followed by platinum-based doublet chemotherapy (excluding docetaxel).
3. Subjects must have at least one measurable lesion according to RECIST v1.1.
Exclusion Criteria
2. Sensitivity mutation of EGFR or ALK fusion.
3. Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Jilin Cancer Hospital
Jilin, Changchun, China
Hunan Cancer Hospital
Hunan, Changsha, China
West China Hospital, Sichuan University
Sichuan, Chengdu, China
Second Affiliated Hospital, PLA Academy of Military Medical Sciences
Chongqing, Chongqing Municipality, China
Army Medical Center, PLA
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University
Guangdong, Guangzhou, China
Harbin Medical University Cancer Hospital
Heilongjiang, Harbin, China
Anyang Tumor Hospital
Anyang, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
The First People's Hospital of Changde
Changde, Hunan, China
The First Affiliated Hospital of Nanchang University
Jiangxi, Nanchang, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
The Third People's Hospital of Datong
Datong, Shanxi, China
Yibin Second People's Hospital
Yibin, Sichuan, China
Affiliated Tumor Hospital of Xinjiang Medical University
Xinjiang, Xinjiang, China
Shanghai Pulmonary Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tongmei Zhang, Doctor
Role: primary
Ying Liu, Doctor
Role: primary
Lin Wu, Doctor
Role: primary
Panwen Tian, Doctor
Role: primary
Bo Zhu, Doctor
Role: primary
Mengxia Li, Doctor
Role: primary
Chengzhi Zhou, Doctor
Role: primary
Yan Yu, Doctor
Role: primary
Yuanyuan Ji, Doctor
Role: primary
Zhiye Zhang, Doctor
Role: primary
Yinghua Ji, Doctor
Role: primary
Zhijun Wu, Doctor
Role: primary
Longhua Sun, Doctor
Role: primary
Peng Zhang, Doctor
Role: primary
Chengxu Cui, Doctor
Role: primary
Xujuan Ye, Doctor
Role: primary
Zhigang Han, Doctor
Role: primary
Chunxia Su, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS207-004-II-NSCLC
Identifier Type: -
Identifier Source: org_study_id